Contemporary Oncology (Jun 2022)
Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer
Abstract
No abstracts available.Keywords